Vigonvita Life Sciences

This study tests an experimental drug called LV232 for people with major depressive disorder. About 400 adults aged 18 to 65 will receive either LV232 or a placebo for 8 weeks to see if it reduces depression symptoms. The goal is to find the best dose and check for side effects.

This early-stage study tests a new drug called VV119 in healthy adults and people with schizophrenia. The main goal is to check safety and how the drug moves through the body. About 40 participants will take multiple doses to see if it is well-tolerated.

This study looks at how eating a standard meal changes the way a new drug, VV119, is processed in the body. It involves 16 healthy Chinese adults who will take a single dose of VV119 with and without food. The goal is to see if food affects drug levels and safety, helping guide f…

This early-stage study tests a single dose of VV913 capsules in 56 healthy Chinese men to see if it is safe and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo. The study does not aim to treat any disease, but to gather import…

This early-stage study tests a single dose of an experimental drug called VV261 in 58 healthy adults aged 18 to 45. The goal is to see if the drug is safe and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo, and no one knows w…